Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

213.35 -9.65 (-4.33%)
Official Closing Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ResMed Inc. Common Stock

< Previous 1 2 3 Next >
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis 
From Resmed, Inc.
Via GlobeNewswire
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
From Resmed, Inc.
Via GlobeNewswire
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of... 
From Resmed, Inc.
Via GlobeNewswire
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone 
From Resmed, Inc.
Via GlobeNewswire
ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships 
From ResMed Inc.
Via GlobeNewswire
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
From ResMed Inc.
Via GlobeNewswire
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the UBS Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025
From ResMed Inc.
Via GlobeNewswire
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
From ResMed Inc.
Via GlobeNewswire
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort 
From ResMed Inc.
Via GlobeNewswire
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort 
From ResMed Inc.
Via GlobeNewswire
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
From ResMed Inc.
Via GlobeNewswire
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
From ResMed Inc.
Via GlobeNewswire
Vaping Expected to Increase COPD Health and Economic Burden by 2050
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
From ResMed Inc.
Via GlobeNewswire
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
From ResMed Inc.
Via GlobeNewswire
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA 
From ResMed Inc.
Via GlobeNewswire
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
The alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes. 
From MatrixCare
Via GlobeNewswire
ResMed Announces Participation in the RBCCM Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
From ResMed Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.